Literature DB >> 21476107

Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.

Tobias Leibold1, Timothy J Akhurst, David B Chessin, Henry W Yeung, Homer Macapinlac, Jinru Shia, Bruce D Minsky, Leonard B Saltz, Elyn Riedel, Madhu Mazumdar, Philip B Paty, Martin R Weiser, W Douglas Wong, Steven M Larson, José G Guillem.   

Abstract

BACKGROUND: Early identification of inadequate response to preoperative chemoradiotherapy (CRT) may spare rectal cancer patients the toxicity of ineffective treatment. We prospectively evaluated tumor response with (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) early in the course of preoperative CRT.
METHODS: A total of 27 prospectively accrued patients with locally advanced rectal cancer (T(3-4)/N(1)) received preoperative CRT (5040 cGy + 5FU-based chemotherapy). Patients underwent PET scanning before and 8-14 days after commencement of CRT. Scans were interpreted using 3 standard parameters: SUV(max), SUV(avg), and total lesion glycolysis (TLG) as well as an investigational parameter: visual response score (VRS). Percent pathologic response was quantified as a continuous variable. All PET parameters were correlated with pathology. Pathologic complete/near-complete response was defined as ≥95% tumor destruction, suboptimal response as <95%. Statistical analysis was performed using the Wilcoxon rank sum test and receiver operating characteristic (ROC) curve analysis.
RESULTS: Of the 27 patients, 11 (41%) had pathologic complete/near-complete response; 16 (59%) had suboptimal response. SUV(max), SUV(avg), and TLG did not discriminate between responders and nonresponders. Visual response score (VRS) was statistically significantly higher for complete/near-complete responders than for suboptimal responders (65 vs. 33%, P = 0.02). Suboptimal responders were identified with 94% sensitivity and 78% accuracy using a VRS cut-off of 50%.
CONCLUSIONS: In this pilot study, FDG-PET at 8-14 days after the beginning of preoperative CRT was unsuccessful at predicting pathological response with enough accuracy to justify an early change in therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476107     DOI: 10.1245/s10434-011-1634-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.

Authors:  Antonio Avallone; Luigi Aloj; Corradina Caracò; Paolo Delrio; Biagio Pecori; Fabiana Tatangelo; Nigel Scott; Rossana Casaretti; Francesca Di Gennaro; Massimo Montano; Lucrezia Silvestro; Alfredo Budillon; Secondo Lastoria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-05       Impact factor: 9.236

2.  Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging.

Authors:  R O Perez; A Habr-Gama; G P São Julião; P B Lynn; C Sabbagh; I Proscurshim; F G Campos; J Gama-Rodrigues; S C Nahas; C A Buchpiguel
Journal:  Tech Coloproctol       Date:  2014-02-08       Impact factor: 3.781

3.  The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.

Authors:  Lucia Leccisotti; Maria Antonietta Gambacorta; Chiara de Waure; Antonella Stefanelli; Brunella Barbaro; Fabio Maria Vecchio; Claudio Coco; Roberto Persiani; Antonio Crucitti; Antonino Pio Tortorelli; Alessandro Giordano; Vincenzo Valentini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-17       Impact factor: 9.236

4.  Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.

Authors:  Natalie J Serkova
Journal:  Drug Resist Updat       Date:  2011-06-02       Impact factor: 18.500

5.  (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer.

Authors:  Junichi Nishimura; Junichi Hasegawa; Yoji Ogawa; Hideaki Miwa; Mamoru Uemura; Naotsugu Haraguchi; Taishi Hata; Hirofumi Yamamoto; Ichiro Takemasa; Tsunekazu Mizushima; Riichiro Nezu; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2015-12-28       Impact factor: 2.549

6.  Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET.

Authors:  Florent Tixier; Mathieu Hatt; Catherine Cheze Le Rest; Adrien Le Pogam; Laurent Corcos; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2012-03-27       Impact factor: 10.057

7.  KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.

Authors:  Oliver S Chow; Deborah Kuk; Metin Keskin; J Joshua Smith; Niedzica Camacho; Raphael Pelossof; Chin-Tung Chen; Zhenbin Chen; Karin Avila; Martin R Weiser; Michael F Berger; Sujata Patil; Emily Bergsland; Julio Garcia-Aguilar
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

8.  Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters.

Authors:  Sun-pyo Hong; Seung Eun Lee; Yoon-La Choi; Sung Wook Seo; Ki-Sun Sung; Hong Hoe Koo; Joon Young Choi
Journal:  Skeletal Radiol       Date:  2014-02-15       Impact factor: 2.199

9.  Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.

Authors:  In Ja Park; Y Nancy You; John M Skibber; Miguel A Rodriguez-Bigas; Barry Feig; Sa Nguyen; Chung-Yuan Hu; George J Chang
Journal:  Dis Colon Rectum       Date:  2013-02       Impact factor: 4.585

10.  Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study.

Authors:  Natalia Goldberg; Yulia Kundel; Ofer Purim; Hanna Bernstine; Noa Gordon; Sara Morgenstern; Efraim Idelevich; Nir Wasserberg; Aaron Sulkes; David Groshar; Baruch Brenner
Journal:  Radiat Oncol       Date:  2012-08-01       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.